# US 8,277,802 B2 · Diagnosis and prevention of cancer cell invasion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,802 B2
- Document ID: US8277802B2
- Status: Granted
- Kind: B2
- Application number: 10/521,410
- Filed: 2003-07-17
- Published: 2005-08-25
- Granted: 2012-10-02
- Earliest claimed: 2002-07-17
- Assignees: Max-Planck-Gesellschaft zur Foederung der Wissenschaften e.V.
- Inventors: Axel Ullrich; Pjotr Knyazev; Tatjana Knyazeva; Yuri Cheburkin; Peter Vajkoczy
- Web page: https://patentgrep.com/patent/US8277802B2

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 2039/505: {comprising antibodies}
- C12Q 2600/136: Screening for pharmacological compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. Most particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion.

## Claims

### Claim 1

A method of reducing the invasivity of cancer cells in a subject in need thereof comprising administering to the subject an inhibitor of the AXL protein or GAS6, or any combination thereof, in an amount which is effective for reducing the invasivity of cancer cells, and wherein said inhibitor of the AXL protein is selected from the group consisting of anti-AXL antibodies or Fab, Fab′, Fab2 or scFV antigen binding fragments thereof, and wherein said inhibitor of GAS6 is selected from the group consisting of anti-GAS6 antibodies or Fab, Fab′, Fab2 or scFV antigen binding fragments thereof,
and wherein said cancer cells are selected from the group consisting of kidney cancer cells and glioblastoma cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein said inhibitor inhibits the receptor tyrosine kinase activity of the AXL protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor of the AXL protein inhibits the interaction between the AXL protein and its ligands.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer cells are glioblastoma cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 6 (depends on 1)

The method of claim 1, wherein the AXL protein inhibitor is an antibody directed against the AXL protein.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein said inhibitor of GAS6 is further selected from the group consisting of Fab, Fab′, Fab2, and scFV antigen binding fragments of the anti-GAS antibodies.

### Claim 9 (depends on 1)

The method of claim 1, wherein said inhibitor inhibits AXL protein activity or the interaction between AXL protein and GAS6, or a combination thereof.
